An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.

Also called NCT05562934

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 189 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05562934
  • EudraCT 2021-005738-41
Other papers using this trial's data
  • Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial Journal of the American College of Cardiology, 2026-05-12 DOI, PubMed 41563174

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Bulgaria, China, Czechia, France, Germany, Italy, Japan, Netherlands, Poland, Slovakia, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05562934. Randomized; triple masking; primary purpose treatment. Start 2022-11-08 (actual); primary completion 2024-07-02 (actual). Results posted on 2025-10-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
Condition
Resistant Hypertension
Intervention (Biological)
XXB750 drug
Intervention (Other)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05562934
Content hash
478c4427e16495cd97536b25ec9f371c6804503d9e717d5f028a8d43ec7fdf4d